Vivolux AB
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Private
- Established
- 2006-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.vivolux.com
Clinical Trials
3
Active:1
Completed:0
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (100.0%)A Study of VLX1570 and Dexamethasone in Myeloma Patients
- First Posted Date
- 2015-02-26
- Last Posted Date
- 2018-05-11
- Lead Sponsor
- Vivolux AB
- Target Recruit Count
- 15
- Registration Number
- NCT02372240
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Study of Safety and Tolerability of VLX600, an Iron Chelator, in Patients With Refractory Advanced Solid Tumors
- First Posted Date
- 2014-08-21
- Last Posted Date
- 2018-05-11
- Lead Sponsor
- Vivolux AB
- Target Recruit Count
- 19
- Registration Number
- NCT02222363
- Locations
- 🇺🇸
Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic Jacksonville, Jacksonville, Florida, United States
🇺🇸Mayo Clinic Rochester, Rochester, Minnesota, United States
News
No news found